REG - Ondine Biomedical - Grant of Options and Warrants

Ondine BiomedicalAnnouncement

29/01/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250129:nRSc1043Va&default-theme=true

RNS Number : 1043V  Ondine Biomedical Inc.  29 January 2025

29 January 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

 

Grant of Options and Warrants

 

Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company developing
light-activated antimicrobial treatments, announces the issuance of options
and warrants as detailed below.

 

Grant of Options

 

On 28 January 2025, Ondine granted a total of 500,000 options to subscribe for
new common shares in the Company ("Options") to its Non-executive Directors as
follows:

 

 Director       Position                Options granted  Exercise price  Total options now held
 Jean Charest   Non-executive Chair     200,000          12 pence        340,000
 Jean Duvall    Non-executive Director  75,000           12 pence        150,000
 Mike Farrar    Non-executive Director  75,000           12 pence        250,000
 Junaid Bajwa   Non-executive Director  75,000           12 pence        150,000
 Margaret Shaw  Non-executive Director  75,000           12 pence        75,000

 

The Options all have an exercise price of 12 pence, being the closing share
price on 28 January 2025 (the "Approval Date"), the day on which the grant of
Options was approved by the Board. The Options vest evenly over a period of
four years, with 25% vesting on each of the four successive anniversaries of
the Approval Date and can be exercised for a period of five years from the
Approval Date.

 

Following the grant of the Options, the Company has 13,105,000 options to
subscribe for new common shares outstanding, which represents 3.24% per cent
of the Company's current issued share capital.

 

The FCA notifications in respect of the above Option grants, made in
accordance with the requirements of the UK Market Abuse Regulation, are
appended below.

 

Issue of Warrants

 

The Company's Board has authorised the issuing of warrants to certain key
vendors. A total of 1,450,000 warrants are to be issued, entitling the holders
to acquire common shares of the Company at a strike price of 17 pence each.
The warrants have an expiration date of 31 December 2025.

 

A total of 250,000 Warrants are to be issued to Livingstone Life Sciences
Limited, a wholly-owned company by former Ondine Board Member and current
Chief Medical Officer, Dr. Simon Sinclair, who is leading Ondine's Phase 3
clinical trial. The Warrants vest immediately upon grant and have an
expiration date of 31 December 2025.

 

 

Enquiries:

 Ondine Biomedical Inc.                                         www.ondinebio.com
 Carolyn Cross, CEO                                            Via Vane Percy & Roberts

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Phil Davies, Sam Butcher                                      +44 (0)20 7496 3000

 RBC Capital Markets (Broker)
 Rupert Walford, Kathryn Deegan                                +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                              +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

  1.     Details of the person discharging managerial responsibilities / person closely
         associated
 a)      Name                                                         1.     Jean Charest

                                                                      2.     Jean Duvall

                                                                      3.     Mike Farrar

                                                                      4.     Junaid Bajwa

                                                                      5.     Margaret Shaw
 2.      Reason for the Notification
 a)      Position/status                                              1.     Non-executive Chair (PDMR)

                                                                      2.     Non-executive Director (PDMR)

                                                                      3.     Non-executive Director (PDMR)

                                                                      4.     Non-executive Director (PDMR)

                                                                      5.     Non-executive Director (PDMR)
 b)      Initial notification/Amendment                               Initial notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name                                                         Ondine Biomedical Inc.
 b)      LEI                                                          213800QO681575J97813
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the Financial instrument, type of instrument  Options to subscribe for Common Shares

         Identification code                                          ISIN: CA68234M2058
 b)      Nature of the transaction                                    Grant of options to subscribe for common shares of no par value
 c)      Price(s) and volume(s)                                       PDMR           Price(s)                              Volume(s)
                                                                      Jean Charest   Exercise price of 12 pence per share  200,000
                                                                      Jean Duvall    Exercise price of 12 pence per share  75,000
                                                                      Mike Farrar    Exercise price of 12 pence per share  75,000
                                                                      Junaid Bajwa   Exercise price of 12 pence per share  75,000
                                                                      Margaret Shaw  Exercise price of 12 pence per share  75,000
 d)      Aggregated information:                                      N/A

         ·Aggregated volume

         ·Price
 e)      Date of the transaction                                      28 January 2025
 f)      Place of the transaction                                     Outside a trading venue

d)

Aggregated information:

·Aggregated volume

·Price

N/A

 

e)

Date of the transaction

28 January 2025

f)

Place of the transaction

Outside a trading venue

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

  1.     Details of the person discharging managerial responsibilities / person closely
         associated
 a)      Name                                                         Simon Sinclair
 2.      Reason for the Notification
 a)      Position/status                                              Former Non-executive Director (PDMR)
 b)      Initial notification/Amendment                               Initial notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name                                                         Ondine Biomedical Inc.
 b)      LEI                                                          213800QO681575J97813
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the Financial instrument, type of instrument  Warrants

         Identification code                                          ISIN: CA68234M2058
 b)      Nature of the transaction                                    Grant of options to subscribe for common shares of no par value
 c)      Price(s) and volume(s)                                       250,000 warrants at a price of 17 pence each
 d)      Aggregated information:                                      N/A

         ·Aggregated volume

         ·Price
 e)      Date of the transaction                                      28 January 2025
 f)      Place of the transaction                                     Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHGRGDBXBDDGUC